Wada S, Udagawa N, Nagata N, Martin T J, Findlay D M
St. Vincent's Institute of Medical Research, Fitzroy, Australia.
Endocrinology. 1996 Jan;137(1):312-20. doi: 10.1210/endo.137.1.8536630.
We have reported that calcitonin (CT) treatment induced downregulation of the CT receptor (CTR) in mouse osteoclast-like cells (OCLs). Here, we studied the features of homologous down-regulation of the CTR in mature mouse OCLs. Treatment with salmon CT (sCT) and human CT (hCT) reduced [125I]sCT specific binding. The decreased binding after 24 h of CT treatment was associated with a decrease in the cell surface receptor concentration. The extent of CT-induced down-regulation in 24 h was dose-dependent, and the ED50 value was 3.6 +/- 4.1 (mean +/- SD; n = 3) x 10(-13 M for sCT and 4.9 +/- 3.3 x 10(-11) M for hCT. These values were very similar to those for the CT inhibition of the bone-resorbing activity of OCLs. The data suggest that these two distinct actions of CT may be mediated by a common intracellular pathway. Treatment of OCLs with activators of protein kinase A (PKA) mimicked the effect of CT on CTR downregulation, whereas neither activation of protein kinase C nor elevation of intracellular Ca2+ did so. Attenuation of CT-induced CTR down-regulation by the competitive cAMP antagonist, RpcAMP, and high concentrations of H-7, but not by protein kinase C-specific inhibitors (sphingosine, staurosporine, and a lower concentration of H-7), suggested that the PKA pathway is primarily involved in homologous regulation of the CTR. The changes in CTR messenger RNA confirm the findings in binding studies and demonstrate that CT treatment of OCLs results in decreased CTR synthesis through the PKA pathway. The low concentrations of hCT that result in CTR regulation are very close to the physiological range, providing new insights into a dynamic relationship between circulating levels of CT and CTR expression in osteoclasts.
我们曾报道,降钙素(CT)处理可诱导小鼠破骨细胞样细胞(OCLs)中CT受体(CTR)的下调。在此,我们研究了成熟小鼠OCLs中CTR同源下调的特征。用鲑鱼降钙素(sCT)和人降钙素(hCT)处理可降低[125I]sCT特异性结合。CT处理24小时后结合减少与细胞表面受体浓度降低有关。CT诱导的24小时下调程度呈剂量依赖性,sCT的半数有效剂量(ED50)值为3.6±4.1(平均值±标准差;n = 3)×10-13 M,hCT为4.9±3.3×10-11 M。这些值与CT抑制OCLs骨吸收活性的值非常相似。数据表明,CT的这两种不同作用可能由共同的细胞内途径介导。用蛋白激酶A(PKA)激活剂处理OCLs可模拟CT对CTR下调的作用,而蛋白激酶C的激活或细胞内Ca2+升高均无此作用。竞争性环磷酸腺苷(cAMP)拮抗剂RpcAMP和高浓度的H-7可减弱CT诱导的CTR下调,但蛋白激酶C特异性抑制剂(鞘氨醇、星形孢菌素和较低浓度的H-7)则无此作用,提示PKA途径主要参与CTR的同源调节。CTR信使核糖核酸(mRNA)的变化证实了结合研究的结果,并表明CT处理OCLs可通过PKA途径导致CTR合成减少。导致CTR调节的低浓度hCT非常接近生理范围,为破骨细胞中循环CT水平与CTR表达之间的动态关系提供了新的见解。